This is HUGE news! The FDA has officially approved Abrysvo, the first RSV vaccine designed for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) AND severe LRTD caused by RSV in infants from birth through 6 months of age. Let’s talk about that! 🧵⬇️🧪
August 23, 2023 at 4:00 PM
This is HUGE news! The FDA has officially approved Abrysvo, the first RSV vaccine designed for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) AND severe LRTD caused by RSV in infants from birth through 6 months of age. Let’s talk about that! 🧵⬇️🧪
On August 21st, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV)
August 23, 2023 at 4:00 PM
On August 21st, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV)
www.thelancet.com/jo...
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.
2/2
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.
2/2
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF
effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation
from birth to age 3 months and sustained to age 6 months.
www.thelancet.com
August 21, 2025 at 11:33 AM
www.thelancet.com/jo...
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.
2/2
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.
2/2
All my VODs from the VTuber Summer Slam back in 2025 are all online!
Come relive the streams here:
www.youtube.com/watch?v=lxwZ...
www.youtube.com/watch?v=lhhF...
www.youtube.com/watch?v=LrTD...
Come relive the streams here:
www.youtube.com/watch?v=lxwZ...
www.youtube.com/watch?v=lhhF...
www.youtube.com/watch?v=LrTD...
March 7, 2026 at 6:12 PM
All my VODs from the VTuber Summer Slam back in 2025 are all online!
Come relive the streams here:
www.youtube.com/watch?v=lxwZ...
www.youtube.com/watch?v=lhhF...
www.youtube.com/watch?v=LrTD...
Come relive the streams here:
www.youtube.com/watch?v=lxwZ...
www.youtube.com/watch?v=lhhF...
www.youtube.com/watch?v=LrTD...
The safety and effectiveness of Abrysvo for immunization of pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age was evaluated in ongoing, randomized, placebo-controlled international clinical studies.
August 23, 2023 at 4:01 PM
The safety and effectiveness of Abrysvo for immunization of pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age was evaluated in ongoing, randomized, placebo-controlled international clinical studies.
Another good news story for safe vaccines.
The RSV vaccine RSVpreF (Abrysvo) was evaluated using a test-negative control study in a high-risk general older clinical population (>60 years) with a lower respiratory tract disease (LRTD) episode requiring hospitalisation or emergency department visit.
The RSV vaccine RSVpreF (Abrysvo) was evaluated using a test-negative control study in a high-risk general older clinical population (>60 years) with a lower respiratory tract disease (LRTD) episode requiring hospitalisation or emergency department visit.
February 5, 2025 at 1:36 AM
Another good news story for safe vaccines.
The RSV vaccine RSVpreF (Abrysvo) was evaluated using a test-negative control study in a high-risk general older clinical population (>60 years) with a lower respiratory tract disease (LRTD) episode requiring hospitalisation or emergency department visit.
The RSV vaccine RSVpreF (Abrysvo) was evaluated using a test-negative control study in a high-risk general older clinical population (>60 years) with a lower respiratory tract disease (LRTD) episode requiring hospitalisation or emergency department visit.
Vaccination during pregnancy lowered the risk of hospitalisation for lung complications in infants in their first 6 months of life by more than 70% - according to a study from Argentina. Argentina is the 1st country to roll out RSV vaccination during pregnancy. www.thelancet.com/journals/lan...
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (B...
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF
effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation
from birth to age 3 months and su...
www.thelancet.com
April 21, 2026 at 8:47 AM
Vaccination during pregnancy lowered the risk of hospitalisation for lung complications in infants in their first 6 months of life by more than 70% - according to a study from Argentina. Argentina is the 1st country to roll out RSV vaccination during pregnancy. www.thelancet.com/journals/lan...
An overview of a new study in adults showing the Abrysvo respiratory syncytial virus (RSV) vaccine preventing lower respiratory tract disease (LRTD) caused by RSV infection among older adults, a group at high risk of severe disease.
A good news RSV vaccine story for adults
An overview of a new study in adults showing the Abrysvo respiratory syncytial virus (RSV) vaccine preventing lower respiratory tract disease (LRTD) caused by RSV infection among older adults, a group at high risk of severe disease. The study's setup The RSV vaccine RSVpreF (Abrysvo) was evaluated using a test-negative control design in a high-risk general older clinical population (>60 years of age) with an LRTD episode requiring hospitalisation or an emergency department (ED) visit.[1]
virologydownunder.com
February 5, 2025 at 2:24 AM
An overview of a new study in adults showing the Abrysvo respiratory syncytial virus (RSV) vaccine preventing lower respiratory tract disease (LRTD) caused by RSV infection among older adults, a group at high risk of severe disease.
A clinical study evaluated the effectiveness of Abrysvo to prevent LRTD and severe LRTD caused by RSV in infants born to individuals who were vaccinated during pregnancy. Among approximately 3,500 pregnant individuals who received Abrysvo, compared to approximately 3,500 pregnant
August 23, 2023 at 4:01 PM
A clinical study evaluated the effectiveness of Abrysvo to prevent LRTD and severe LRTD caused by RSV in infants born to individuals who were vaccinated during pregnancy. Among approximately 3,500 pregnant individuals who received Abrysvo, compared to approximately 3,500 pregnant
Some mine for gold, looks like they're mining for milkalcum. Under certain conditions it gives off a rainbow glow.
LRTD:
@bernardbeawowo.bsky.social
@guntherfoxy35.bsky.social
@jasperbeaw.bsky.social
🐮 Le moo 🐮
#minotaur #bull #bear #tanuki #cave #NSFW #gay #cum #rainbowcum
#art #sex #onlymoos
LRTD:
@bernardbeawowo.bsky.social
@guntherfoxy35.bsky.social
@jasperbeaw.bsky.social
🐮 Le moo 🐮
#minotaur #bull #bear #tanuki #cave #NSFW #gay #cum #rainbowcum
#art #sex #onlymoos
June 29, 2026 at 4:49 PM
Some mine for gold, looks like they're mining for milkalcum. Under certain conditions it gives off a rainbow glow.
LRTD:
@bernardbeawowo.bsky.social
@guntherfoxy35.bsky.social
@jasperbeaw.bsky.social
🐮 Le moo 🐮
#minotaur #bull #bear #tanuki #cave #NSFW #gay #cum #rainbowcum
#art #sex #onlymoos
LRTD:
@bernardbeawowo.bsky.social
@guntherfoxy35.bsky.social
@jasperbeaw.bsky.social
🐮 Le moo 🐮
#minotaur #bull #bear #tanuki #cave #NSFW #gay #cum #rainbowcum
#art #sex #onlymoos
Sorry anyone here who reads my fanfic. LRTD is officially abandoned. I won't say why but it's 99% likely never coming back. Thank you to anyone who read and enjoyed it. I really appreciated it.
October 6, 2026 at 9:07 PM
Sorry anyone here who reads my fanfic. LRTD is officially abandoned. I won't say why but it's 99% likely never coming back. Thank you to anyone who read and enjoyed it. I really appreciated it.
The vaccine was previously approved for all adults aged 60 and over and those aged 50 to 59 at increased risk of LRTD caused by RSV.
www.cidrap.umn.edu/respiratory-...
www.cidrap.umn.edu/respiratory-...
FDA approves use of RSV vaccine in at-risk younger adults
The FDA has approved GSK's Arexvy for adults aged 18 to 49 who have increased risk of complications from the virus.
www.cidrap.umn.edu
March 16, 2026 at 3:00 PM
The vaccine was previously approved for all adults aged 60 and over and those aged 50 to 59 at increased risk of LRTD caused by RSV.
www.cidrap.umn.edu/respiratory-...
www.cidrap.umn.edu/respiratory-...
New research:
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina
www.thelancet.com/journals/lan...
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina
www.thelancet.com/journals/lan...
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (B...
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF
effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation
from birth to age 3 months and su...
www.thelancet.com
May 6, 2025 at 6:48 AM
New research:
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina
www.thelancet.com/journals/lan...
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina
www.thelancet.com/journals/lan...
Real world effectiveness of maternal RSV vaccination looks pretty awesome: 77% against RSV-associated severe LRTD leading to hospitalisation from birth to age 6 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00156-2/abstract
August 21, 2025 at 7:34 PM
Real world effectiveness of maternal RSV vaccination looks pretty awesome: 77% against RSV-associated severe LRTD leading to hospitalisation from birth to age 6 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00156-2/abstract
and 1,500 received placebo, Abrysvo reduced the risk of LRTD by 34.7%, and reduced the risk of severe LRTD by 91.1% within 90 days after birth when compared to placebo. Within 180 days after birth, Abrysvo reduced the risk of LRTD by 57.3% and by 76.5% for severe LRTD.
August 23, 2023 at 4:02 PM
and 1,500 received placebo, Abrysvo reduced the risk of LRTD by 34.7%, and reduced the risk of severe LRTD by 91.1% within 90 days after birth when compared to placebo. Within 180 days after birth, Abrysvo reduced the risk of LRTD by 57.3% and by 76.5% for severe LRTD.
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study) www.thelancet.com/journals/lan...
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (B...
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF
effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation
from birth to age 3 months and su...
www.thelancet.com
August 24, 2025 at 1:49 AM
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study) www.thelancet.com/journals/lan...
De werkzaamheid van nirsevimab is niet alleen gebaseerd op fabrikantdata. Real-world studies laten circa 87% bescherming tegen RSV-LRTD en tot 98% tegen RSV-opname zien. Dat bevestigt de trialresultaten.
publications.aap.org...
7/10
publications.aap.org...
7/10
September 6, 2026 at 2:14 PM
De werkzaamheid van nirsevimab is niet alleen gebaseerd op fabrikantdata. Real-world studies laten circa 87% bescherming tegen RSV-LRTD en tot 98% tegen RSV-opname zien. Dat bevestigt de trialresultaten.
publications.aap.org...
7/10
publications.aap.org...
7/10
NOTE: The FDA approved Abrysvo in late May for the prevention of LRTD caused by RSV in individuals 60 years of age and older and is already available at certain Walgreens locations.
• www.cnbc.com/2023/05/31/f...
• www.cnbc.com/2023/05/31/f...
August 23, 2023 at 4:01 PM
NOTE: The FDA approved Abrysvo in late May for the prevention of LRTD caused by RSV in individuals 60 years of age and older and is already available at certain Walgreens locations.
• www.cnbc.com/2023/05/31/f...
• www.cnbc.com/2023/05/31/f...
individuals who received placebo, Abrysvo reduced the risk of severe LRTD by 81.8% within 90 days after birth, and 69.4% within 180 days after birth. In a subgroup of pregnant individuals who were 32 through 36 weeks gestational age, of whom approximately 1,500 received Abrysvo
August 23, 2023 at 4:02 PM
individuals who received placebo, Abrysvo reduced the risk of severe LRTD by 81.8% within 90 days after birth, and 69.4% within 180 days after birth. In a subgroup of pregnant individuals who were 32 through 36 weeks gestational age, of whom approximately 1,500 received Abrysvo
📈 New phase 3 data presented at #ESCMIDGlobal
Efficacy, safety, and immunogenicity of the #RSV prefusion F protein vaccine in older adults over three RSV seasons
Results support a beneficial effect for at least three RSV seasons
@michaelisonmd.bsky.social
🔗 tinyurl.com/5b87kh9x
Efficacy, safety, and immunogenicity of the #RSV prefusion F protein vaccine in older adults over three RSV seasons
Results support a beneficial effect for at least three RSV seasons
@michaelisonmd.bsky.social
🔗 tinyurl.com/5b87kh9x
April 15, 2025 at 7:57 AM
📈 New phase 3 data presented at #ESCMIDGlobal
Efficacy, safety, and immunogenicity of the #RSV prefusion F protein vaccine in older adults over three RSV seasons
Results support a beneficial effect for at least three RSV seasons
@michaelisonmd.bsky.social
🔗 tinyurl.com/5b87kh9x
Efficacy, safety, and immunogenicity of the #RSV prefusion F protein vaccine in older adults over three RSV seasons
Results support a beneficial effect for at least three RSV seasons
@michaelisonmd.bsky.social
🔗 tinyurl.com/5b87kh9x
Thread 🧵🧪 Medsky Immunosky Episky
Pfizer reported (by press release) that Abrysvo (their RSV vaccine) held strong through a second season of RSV at an efficacy of 77.8% (95.0% CI: 51.4, 91.1), down from 88.9% (95.0% CI: 53.6%, 98.7%) against RSV LRTD w/ 3+ symptoms:
www.pfizer.com/news/press-r...
Pfizer reported (by press release) that Abrysvo (their RSV vaccine) held strong through a second season of RSV at an efficacy of 77.8% (95.0% CI: 51.4, 91.1), down from 88.9% (95.0% CI: 53.6%, 98.7%) against RSV LRTD w/ 3+ symptoms:
www.pfizer.com/news/press-r...
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults | Pfizer
ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower res...
www.pfizer.com
May 31, 2024 at 5:37 PM
Thread 🧵🧪 Medsky Immunosky Episky
Pfizer reported (by press release) that Abrysvo (their RSV vaccine) held strong through a second season of RSV at an efficacy of 77.8% (95.0% CI: 51.4, 91.1), down from 88.9% (95.0% CI: 53.6%, 98.7%) against RSV LRTD w/ 3+ symptoms:
www.pfizer.com/news/press-r...
Pfizer reported (by press release) that Abrysvo (their RSV vaccine) held strong through a second season of RSV at an efficacy of 77.8% (95.0% CI: 51.4, 91.1), down from 88.9% (95.0% CI: 53.6%, 98.7%) against RSV LRTD w/ 3+ symptoms:
www.pfizer.com/news/press-r...
lrtd pretent they sgare them eveltualy 🤗
January 8, 2025 at 5:11 AM
lrtd pretent they sgare them eveltualy 🤗
There’s an RSV- LRTD for 50+, ask for Arexvy
November 15, 2024 at 4:18 AM
There’s an RSV- LRTD for 50+, ask for Arexvy